1-乙氧基-2-甲基丙烷-2-胺 | 89585-15-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-乙氧基-2-甲基丙烷-2-胺
• 英文名称: β-Aethoxy-α,α-dimethyl-aethylamin
• 英文别名: 1-Ethoxy-2-methylpropan-2-amine
• CAS: 89585-15-9
• 化学式: C₆H₁₅NO
• mdl: MFCD11053901
• 分子量: 117.191
• InChiKey: CSHMRHZWHFQJRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2922199090

反应信息

• 作为产物：
  描述：

  2,2-二甲基氮丙啶 、 乙醇 生成 1-乙氧基-2-甲基丙烷-2-胺
  参考文献：
  名称：

  Harder,U. et al., Chemische Berichte, 1964, vol. 97, p. 510 - 519

  摘要：

  DOI：

文献信息

• FUNGICIDES
  申请人：Murphy Kessabi Fiona

  公开号：US20100056570A1

  公开（公告）日：2010-03-04

  Compounds of the general formula wherein the substituents are as defined in claim ( 1 ), are useful as fungicides.

  通式为（公式），其中取代基如权利要求（1）所定义的化合物，可用作杀真菌剂。
• NOVEL URACIL COMPOUND OR SALT THEREOF HAVING HUMAN DEOXYURIDINE TRIPHOSPHATASE INHIBITORY ACTIVITY
  申请人：Fukuoka Masayoshi

  公开号：US20110082163A1

  公开（公告）日：2011-04-07

  Provided is a uracil compound or a salt thereof, which has potent human dUTPase inhibitory activity and is useful as, for example, an antitumor drug. A uracil compound represented by the general formula (I) or a salt thereof: wherein n represents an integer of 1 to 3; X represents a bond, an oxygen atom, a sulfur atom, or the like; Y represents a linear or branched alkylene group having 1 to 8 carbon atoms, or the like; and Z represents —SO 2 NR 1 R 2 or —NR 3 SO 2 —R 4 , wherein R 1 and R 2 each represent an alkyl group having 1 to 6 carbon atoms, an aralkyl group which is optionally substituted, or the like; R 3 represents an alkyl group having 1 to 6 carbon atoms, or the like; and R 4 represents an aromatic hydrocarbon group, an unsaturated heterocyclic group, or the like.

  提供了一种尿嘧啶化合物或其盐，具有强效的人类dUTPase抑制活性，可用作例如抗肿瘤药物。一种由通式（I）表示的尿嘧啶化合物或其盐：其中n表示1至3的整数；X表示键，氧原子，硫原子或类似物；Y表示具有1至8个碳原子的线性或支链烷基或类似物；Z表示—SO2NR1R2或—NR3SO2—R4，其中R1和R2分别表示具有1至6个碳原子的烷基，可选择取代的芳基烷基或类似物；R3表示具有1至6个碳原子的烷基或类似物；R4表示芳香族碳氢基，不饱和杂环基或类似物。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• MULTI-LAYER COMPOSITE ARTICLE INCLUDING POLYURETHANE LAYER AND PC/ABS LAYER
  申请人：Trinseo Europe GmbH

  公开号：EP3293222A1

  公开（公告）日：2018-03-14

  The teachings herein are directed to multi-layered articles, methods for making the multi-layered articles, and polymeric compositions for the multi-layered articles. The multi-layered article includes a substrate layer and a cover layer. The substrate layer is a polymeric composition including a polycarbonate, a styrene containing polymer and wollastonite and the cover layer is made of polyurethane. The substrate forms a durable bond to the cover layer that maintains adhesion even after heat and climate aging.

  本文所授内容涉及多层制品、制造多层制品的方法以及用于多层制品的聚合物组合物。多层制品包括基底层和覆盖层。基底层是一种聚合物组合物，包括聚碳酸酯、含苯乙烯聚合物和硅灰石，覆盖层由聚氨酯制成。基底层与覆盖层形成持久的粘合力，即使经过高温和气候老化也能保持粘合力。